


Breakdown of the EFPIA contribution as of the end of 2016


Series 1 Data Labels

IMI1 in-kind contribution by company




Companies listed under 'Other' are: Abbott, AiCuris Anti-infective Cures GmbH, Almirall, Amgen, Astellas Pharma Europe, Basilea, Biogen Idec, Bristol Myers Squibb, Chiesi Farmaceutici, Eisai, Farmaindustria, Grünenthal, INFARMA, Ipsen, Laboratorios del Dr Esteve, Menarini, Merck Sharp & Dohme, Novo Nordisk, Orion Corporation, Sanofi-Aventis Groupe, Sigma-Tau, Takeda, VFA, Vifor

IMI1 in-kind contribution by category



IMI2 in-kind contribution by organisation



Organisations included under 'Other' are: AbbVie, Actelion Pharmaceuticals, Amgen, Bayer Pharma, Biogen Idec Limited, Boehringer Ingelheim, Bristol-Myers Squibb Company, EFPIA, F. Hoffmann-La Roche, GE Healthcare, Grünenthal, H. Lundbeck, Institute de Recherche Servier, Intervet International, IPSEN Innovation, JDRF International, Merck, MSD IT Global Innovation Center, Novartis Pharma, Novo Nordisk, Pfizer Limited, Piramal Imaging, Takeda Development Centre Europe Ltd., The Leona M. and Harry B. Helmsley Charitable Trust, UCB Biopharma.

EFPIA in-kind contribution to IMI2 by category

